Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Gains from Investment Securities: 2022-2025

Historic Gains from Investment Securities for Entrada Therapeutics (TRDA) over the last 3 years, with Sep 2025 value amounting to -$36,000.

  • Entrada Therapeutics' Gains from Investment Securities fell 3500.00% to -$36,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 90.22%. This contributed to the annual value of $4.6 million for FY2024, which is 94.04% down from last year.
  • Entrada Therapeutics' Gains from Investment Securities amounted to -$36,000 in Q3 2025, which was up 10.00% from -$40,000 recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Gains from Investment Securities registered a high of $69.0 million during Q2 2023, and its lowest value of -$33.0 million during Q2 2022.
  • Its 3-year average for Gains from Investment Securities is $9.1 million, with a median of -$28,000 in 2024.
  • In the last 5 years, Entrada Therapeutics' Gains from Investment Securities soared by 309.02% in 2023 and then tumbled by 3,500.00% in 2025.
  • Entrada Therapeutics' Gains from Investment Securities (Quarterly) stood at $4.3 million in 2022, then skyrocketed by 309.02% to $69.0 million in 2023, then tumbled by 102.92% to $6.7 million in 2024, then crashed by 3,500.00% to -$36,000 in 2025.
  • Its last three reported values are -$36,000 in Q3 2025, -$40,000 for Q2 2025, and -$45,000 during Q1 2025.